ArticleWorld journal of surgical oncology2021
Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases.
Article in World journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Very young age stratification and development of a multiple-imputation Cox nomogram for disease-free survival in breast cancer women aged ≤40 years.The oncologist · 2026Article
- Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary Cohort.Cancers · 2025Article
- Long-Term Locoregional Outcomes in a Contemporary Cohort of Young Women With Breast Cancer.JAMA surgery · 2025Article
- Tumour biology and survival outcomes in young women with breast cancer: single-centre retrospective analysis.BJS open · 2024Article
- The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer.Discover oncology · 2024Article
- Association and predictive value of contrast‑enhanced ultrasound features with axillary lymph node metastasis in primary breast cancer.Oncology letters · 2024Article
- Taxane chemotherapy induces stromal injury that leads to breast cancer dormancy escape.PLoS biology · 2023Article
- What Is Known about Breast Cancer in Young Women?Cancers · 2023Review
- Construction and validation of a nomogram for predicting the prognosis of patients with lymph node-positive invasive micropapillary carcinoma of the breast: based on SEER database and external validation cohort.Frontiers in oncology · 2023Article
- Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database.Gland surgery · 2022Article
- Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes.BMC women's health · 2022Article
- Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates.World journal of surgical oncology · 2022Article
- Impact of the ACOSOG Z0011 trial on surgical practice in Asian patients: trends in axillary surgery for breast cancer from a Korean Breast Cancer Registry analysis.World journal of surgical oncology · 2022Article
- Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring.Frontiers in immunology · 2022Article
- Identification of a novel glycolysis-related signature to predict the prognosis of patients with breast cancer.World journal of surgical oncology · 2021Article
- Over-expression of SRD5A3 and its prognostic significance in breast cancer.World journal of surgical oncology · 2021Article
- False-negative frozen section of sentinel nodes in early breast cancer (cT1-2N0) patients.World journal of surgical oncology · 2021Article
- Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.Disease markers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe number of young patients diagnosed with breast cancer is on the rise. We studied the rate trend of local recurrence (LR) and regional recurrence (RR) in young breast cancer (YBC) patients and outcomes among these patients based on molecular subtypes.
methodsA retrospective cohort study was conducted based on data from Tianjin Medical University Cancer Institute and Hospital for patients ≤ 35 years of age with pathologically confirmed primary invasive breast cancer surgically treated between 2006 and 2014. Patients were categorized according to molecular subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year rates for LR, RR, and distant metastases (DM) were estimated by Kaplan-Meir statistics. Nelson-Aalen cumulative-hazard plots were used to describe local recurrence- and distant metastasis-free intervals.
resultsWe identified 25,284 patients with a median follow-up of 82 months, of whom 1099 (4.3%) were YBC patients ≤ 35 years of age. The overall 5-year LR, RR, and DM rates in YBC patients were 6.7%, 5.1%, and 16.6%, respectively. The LR and RR rates demonstrated a decreasing trend over time (P = 0.028 and P = 0.015, respectively). We found that early-stage breast cancer and less lymph node metastases increased over time (P = 0.004 and P = 0.007, respectively). Patients with HR-/HER2+ status had a significantly higher LR (HR 20.4; 95% CI, 11.8-35.4) and DM (HR 37.2; 95% CI, 24.6-56.3) at 10 years. Breast-conserving surgery (BCS) or mastectomy did not influence rates of LR and RR. In the overall population, the 5-year survival of YBC patients exceeded 90%.
conclusionsThe rates of LR and RR with YBC patients demonstrated a downward trend and the proportion of early-stage breast cancer increased between 2006 and 2014. We report the highest LR rates in this young population were associated with HR-/HER2+ tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.